<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00817258</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-0701</org_study_id>
    <nct_id>NCT00817258</nct_id>
  </id_info>
  <brief_title>Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma</brief_title>
  <official_title>Phase â…¡ Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the overall survival in patients with&#xD;
      stage II (T1-2N1M0) NPC treated with concurrent chemotherapy and radiotherapy.&#xD;
&#xD;
      Secondary objectives of the study are to evaluate the disease free survival, and distant&#xD;
      metastases free survival of patients with stage II NPC treated with this regimen&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiotherapy alone is the standard treatment for early stage NPC. In retrospective study of&#xD;
      early stage NPC patients treated with radiotherapy alone. Patients who had Stage II disease&#xD;
      had a worse outcome compared with patients with stage I disease. Chemotherapy, delivered&#xD;
      concurrently with radiation therapy, has been adopted as standard treatment for locally&#xD;
      advanced NPC. However, concurrent chemoradiation for stage II NPC patients has never been&#xD;
      prospectively studied. In the present trial, we hope to assess the value of concurrent&#xD;
      chemotherapy and radiotherapy in patients with stage II (T1-2N1) NPC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 and 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease-free survival, and distant metastases free survival</measure>
    <time_frame>3 and 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients will receive radical radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Cisplatin 40mg/m2,weekly</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)</intervention_name>
    <description>3D-CRT or IMRT</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven differentiated non-keratinizing carcinoma, and undifferentiated&#xD;
             carcinoma of the nasopharynx.&#xD;
&#xD;
          -  Stage II disease (T1-2; N1; M0)&#xD;
&#xD;
          -  KPS &gt;70&#xD;
&#xD;
          -  Age between 18-70&#xD;
&#xD;
          -  Patients should have adequate bone marrow function defined as an absolute peripheral&#xD;
             granulocyte count (AGC) of &gt; 2000 cells/mm3, platelet count of &gt; 100,000 cells/mm3&#xD;
             (pre treatment without intervention). Bilirubin &lt; 1.5 mg/dl, AST or ALT&lt;2 x upper&#xD;
             normal, serum creatinine&lt;1.5mg/dl, creatinine clearance &gt;50ml/min.&#xD;
&#xD;
          -  No prior radiation treatment to the head and neck or any prior chemotherapy&#xD;
&#xD;
          -  Patients with no prior malignancy (not include basal cell carcinoma of skin)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of metastases (below the clavicle or distant) by clinical or radiographic&#xD;
             examinations.&#xD;
&#xD;
          -  Prior radiotherapy to the head and neck region for any reason.&#xD;
&#xD;
          -  Initial surgical treatment excluding diagnostic biopsy of the primary site or neck&#xD;
             disease.&#xD;
&#xD;
          -  Patients with previous or simultaneous primaries, excluding basal cell carcinoma or&#xD;
             squamous cell carcinoma of skin.&#xD;
&#xD;
          -  Pregnant women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Kong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, Cancer Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chaosu Hu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, Cancer Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Kong, MD</last_name>
    <phone>8621-64175590</phone>
    <phone_ext>3900</phone_ext>
    <email>konglinj@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Cancer Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Yuan</last_name>
      <phone>8621-64175590</phone>
      <phone_ext>6511</phone_ext>
      <email>skelly_sh@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>January 2, 2009</study_first_submitted>
  <study_first_submitted_qc>January 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2009</study_first_posted>
  <last_update_submitted>January 5, 2009</last_update_submitted>
  <last_update_submitted_qc>January 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Department of Radiation Oncology,Cancer Hospital, Fudan University, Shanghai, China</name_title>
    <organization>Cancer Hospital, Fudan University, Shanghai, China</organization>
  </responsible_party>
  <keyword>Phase 2 Clinical Trial</keyword>
  <keyword>NPC</keyword>
  <keyword>radiation therapy</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

